902
Participants
Start Date
January 27, 2020
Primary Completion Date
April 12, 2021
Study Completion Date
May 21, 2021
botulinum toxin neuromodulator
A dose of QM1114-DP will be injected in the GL area and in the LCL area.
SkinDC, PLLC, Arlington
Hamilton Research LLC, Alpharetta
Miami Skin and Vein LLC, Coral Gables
Mayoral Dermatology, Coral Gables
Skin Research Institute, LLC, Coral Gables
Center for Clinical and Cosmetic Research, Aventura
Research Institute of SouthEast, LLC, West Palm Beach
Steven Fagien, MD, PA, Boca Raton
Susan H. Weinkle, M.D, Bradenton
Total Skin and Beauty Dermatology Center, PC, Birmingham
Aventiv Research, Inc., Dublin
Elite Aesthetic Research, Cincinnati
EthiQ2 Research, LLC, Mequon
Chicago Cosmetic Surgery and Dermatology, Inc, Chicago
Pure Dermatology, LLC, Metairie
Dallas Plastic Surgery Institute, Dallas
Center for Advanced Clinical Research, Dallas
Austin Institute for Clinical Research, Inc., Pflugerville
AboutSkin Research, LLC, Greenwood Village
Investigate MD, LLC., Scottsdale
Rejuva Medical Aesthetics, LLC, Los Angeles
Westside Aesthetics, Los Angeles
Marcus Facial Plastic Surgery, Redondo Beach
The Maas Clinic Research Center, San Francisco
Center for Dermatology Clinical Research, Inc., Fremont
ArteMedica, Santa Rosa
Modern Dermatology PC, Westport
SkinCare Physicians, Chestnut Hill
Skin Laser and Surgery Specialist of NY/NJ, Hackensack
Jose Raul Montes Eyes & Facial Rejuvenation LLC, San Juan
Lead Sponsor
Galderma R&D
INDUSTRY